Physician profile
Lisa Mazzullo
NPI 1952354342
$2,243.36
in general payments reported to CMS, 2019-2025
23 companies · $645 in 2025
The $645 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $175 · 2021: $102 · 2022: $37.60 · 2023: $318 · 2024: $491 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $518.33 | 2019-2025 | |
| Exeltis, USA INC. | $197.78 | 2024-2025 | Slynd |
| Astellas Pharma US INC | $161.12 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $151.53 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $139.97 | 2023-2025 | |
| Allergan, INC. | $132.61 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $119.11 | 2019-2024 | Gardasil, Gardasil 9 |
| Organon LLC | $115.76 | 2022-2025 | Nexplanon |
| Biogen, INC. | $84.68 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $77.68 | 2023-2025 | Aptima, Omni Hysteroscope, Myosure Tissue Removal Device |
| Therapeuticsmd, INC. | $76.19 | 2019-2021 | |
| Coopersurgical, INC. | $75.16 | 2019-2025 | Paragard T 380a |
| Channel Medsystems, INC. | $67.83 | 2023-2025 | |
| Millicent US INC | $58.61 | 2025 | Intrarosa, Femlyv |
| Exact Sciences Corporation | $56.45 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $35.14 | 2023 | Bd Max System, Bd Max Instrument |
| Lupin INC. | $34.54 | 2019-2020 | |
| Novo Nordisk INC | $33.13 | 2023-2024 | Wegovy |
| Mission Pharmacal Company | $27.75 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.63 | 2019 | |
| Pfizer INC. | $17.60 | 2024 | |
| Dysis Medical, INC. | $17.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mazzullo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.